|
EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors. |
| |
|
Consulting or Advisory Role - AstraZeneca; BeiGene; Blueprint Genetics; Boehringer Ingelheim; Celgene; Daiichi Sankyo/Astra Zeneca; Eisai; Genentech; Janssen; Lilly; Merck; Pfizer; Sanofi/Regeneron; Shionogi; Turning Point Therapeutics |
Speakers' Bureau - AstraZeneca (I); Roche/Genentech (I) |
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Incyte (Inst); Macrogenics (Inst); Merck Sharp & Dohme (Inst) |
| |
|
Research Funding - Bristol Myers Squibb |
| |
|
Leadership - Next Oncology (Inst) |
Stock and Other Ownership Interests - Lilly |
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda |
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda |
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); nalo therapeutics (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron; Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst); Trovagene (Inst) |
| |
|
Honoraria - Amgen (Inst); AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche/Genentech |
Consulting or Advisory Role - Amgen; AstraZeneca; BeiGene; Bristol-Myers Squibb; GlaxoSmithKline (Inst); Janssen; Lilly; Merck Sharp & Dohme; Novartis (Inst); Pfizer (Inst); Roche/Genentech; Takeda |
Research Funding - Sanofi (Inst) |
Patents, Royalties, Other Intellectual Property - UpToDate |
| |
|
Consulting or Advisory Role - Abbvie; ArriVent Biopharma; AstraZeneca; Blueprint Medicines; Daiichi Sankyo/Lilly; EMD Serono; Hengrui Therapeutics; Janssen Oncology; Lilly; Novartis; Sensei Biotherapeutics; Spectrum Pharmaceuticals |
Research Funding - ArriVent Biopharma (Inst); Boehringer Ingelheim (Inst); Lilly (Inst); Regeneron (Inst); Teligene (Inst) |
Travel, Accommodations, Expenses - EMD Serono; Spectrum Pharmaceuticals |
| |
|
Consulting or Advisory Role - Archer; Bayer; Boston Pharmaceuticals; Bristol-Myers Squibb; Daiichi Sankyo Pharmaceutical; Eisai; EMD Serono; General Dynamics Information Technology; Inivata; Janssen Scientific Affairs; Mirati Therapeutics; Novartis; Pfizer; Sanofi/Regeneron |
Speakers' Bureau - AstraZeneca; Clinical Education Alliance; Cor2Ed; Guardant Health; Intellisphere; Merck Sharp & Dohme; Roche |
| |
|
Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celgene; Janssen; Lilly O.; Merck; Novartis; Pfizer; Roche; Samsung; Sanofi |
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo Pharmaceutical; Janssen; Lilly O.; Merck; Novartis; Pfizer; Roche; Samsung; Sanofi |
Other Relationship - Abbvie (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo Pharmaceutical (Inst); Janssen (Inst); Lilly O. (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Sanofi/Aventis (Inst); Taiho Pharmaceutical (Inst) |
| |
|
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BerGenBio; Bristol Myers Squibb; Daiichi Sankyo Europe GmbH; F. Hoffmann LaRoche; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Peptomyc; Pfizer; Sanofi; Takeda; Turning Point Therapeutics |
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb; F. Hoffmann LaRoche; Janssen; Lilly; Medical Trends; Medscape; Merck Serono; Merck Sharp & Dohme; PeerVoice; Pfizer; Sanofi; Takeda; Touch Oncology |
Research Funding - Merck (Inst); Merck KGaA (Inst) |
Other Relationship - GRIFOLS |
| |
|
Honoraria - AstraZeneca; BeiGene Beijing; Boehringer Ingelheim; Bristol-Myers Squibb/China; Hengrui Pharmaceutical; Lilly; MSD Oncology; Pfizer; Roche |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche; Takeda |
Research Funding - BMS (Inst); Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst) |
| |
|
Honoraria - Amgen; AstraZeneca; Lilly; Merck Serono; MSD; TAKEDA; YUHAN |
Consulting or Advisory Role - Alpha pharmaceutical; Amgen; AstraZeneca; Lilly; Merck Serono; MSD; Pfizer; TAKEDA; YUHAN |
|
| |
|
Honoraria - Coherus Biosciences; Merck; Nanobiotix |
Consulting or Advisory Role - Bayer; BioNTech SE; BostonGene; CUE Biopharma; Innate Pharma; IO Biotech; Merck; Nanobiotix; Nektar; Sanofi; VIR Biotechnology |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cue Biopharma (Inst); Dracen (Inst); Genentech/Roche (Inst); Merck (Inst); Nanobiotix (Inst); Regeneron (Inst) |
Travel, Accommodations, Expenses - BostonGene; Coherus Biosciences; Nanobiotix |
| |
|
Honoraria - Amgen; Amgen; Amoy Diagnostics; AstraZeneca Japan; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health; Janssen; Life Technologies; Lilly Japan; Medpace; Merck; Novartis; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Takeda |
Consulting or Advisory Role - Amgen; Bayer; Janssen; Lilly Japan; Medpace |
Research Funding - Amgen (Inst); Amgen (Inst); Amgen Astellas BioPharma (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb K.K. (Inst); Chugai Pharma (Inst); DAIICHI SANKYO Co., Ltd. (Inst); Eisai (Inst); Ignyta (Inst); Janssen (Inst); Kissei Pharmaceutical (Inst); Kyowa Kirin Co., Ltd. (Inst); Lilly Japan (Inst); Loxo (Inst); MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. (Inst); Merck (Inst); Merus (Inst); MSD K.K. (Inst); NEC Corporation (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shanghai HaiHe Pharmaceutical (Inst); Spectrum Pharmaceuticals (Inst); Sumitomo Dainippon Pharma Co., Ltd. (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Thermo Fisher Scientific (Inst); Turning Point Therapeutics (Inst) |
| |
|
|
| |
|
|
Stock and Other Ownership Interests - AstraZeneca |
| |
|
|
Stock and Other Ownership Interests - AstraZeneca |
| |
|
|
Stock and Other Ownership Interests - AstraZeneca; Jounce Therapeutics |
| |
|
|
Stock and Other Ownership Interests - AstraZeneca; GlaxoSmithKline |
| |
|
|
| |
|
No Relationships to Disclose |
| |
|
Honoraria - AstraZeneca; Merck |
Consulting or Advisory Role - Abbvie; Bristol Myers Squibb Foundation; Daiichi Sankyo Co.; Genentech/Roche; Janssen Scientific Affairs; Lilly; Merck; Sanofi |
Speakers' Bureau - AstraZeneca; Lilly; Merck; Mirati Therapeutics; Takeda |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Merck (Inst); Pfizer (Inst); Tessa Therapeutics (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Pfizer |